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Abstract The Wilms’ tumour suppressor gene, WT1, encodes a
zinc finger transcription factor that has been shown to repress a
variety of cellular promoters via binding to cognate DNA
elements. Our earlier work identified an antisense WT1
promoter that contains WT1 consensus sites, but is transcrip-
tionally activated by WT1. In this study, we demonstrate that,
unlike previous reports of transcriptional regulation by WT1,
transactivation of the antisense promoter is unique to a single
isoform of WT1. Of the four alternatively spliced isoforms in
which exon 5 (at splice I) or amino acid residues KTS (at splice
II) are inserted or omitted, only the WT1 isoform containing
splice I and omitting splice II (WT1[+/3]) displays transactiva-
tion. We demonstrate that transregulation variations observed
with WT1 isoforms are not solely attributable to differential
DNA binding by [+KTS] or [3KTS] isoforms. Thus, the
transactivation of the antisense promoter displays an absolute
requirement for exon 5, suggesting that interaction between WT1
and other cellular factors is necessary for this regulatory
function.
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1. Introduction
WT1 is a tumour suppressor gene associated with Wilms’
tumour, an embryonal kidney tumour arising from malignant
transformation of renal stem cells. The consequences of germ-
line defects in the WT1 gene are well-illustrated by two con-
genital syndromes, Denys-Drash syndrome (DDS) and Wilms’
tumour, aniridia, genito-urinary abnormalities and mental re-
tardation (WAGR), which present overlapping sets of growth
and developmental aberrations and a predisposition to Wilms’
tumour. Missense mutations of the WT1 gene are found in
almost all cases of DDS and large deletions at the 11p13 locus
result in WAGR. Additionally, up to 10% of sporadic Wilms’
tumours also have WT1 mutations (reviewed in Hastie, 1994
[1]).
WT1 expression is stringently regulated during organogen-
esis and cell di¡erentiation. In the developing kidney, WT1
expression is low in the condensing mesenchyme but rises as
cells progress towards an immature epithelial cell phenotype.
Expression then attenuates as epithelial cells mature [2]. The
requirement for WT1 in normal nephrogenic di¡erentiation is
highlighted by urogenital defects in WT1 null mice [3], which
also develop abnormalities of the lung and heart. A role for
WT1 in other cell-types is suggested by the decrease of WT1
expression accompanying chemically induced di¡erentiation
of haematopoietic cells [4,5] and the expression of WT1 in
breast tissue [6] and colonic mucosa [7].
The WT1 gene encodes 52^54 kDa nuclear proteins char-
acteristic of zinc ¢nger transcription factors, with a glutamine-
proline-rich trans-regulatory domain and a DNA binding car-
boxy-terminal region [8,9]. The WT1 protein is expressed as
four major isoforms arising from two alternative splice sites (I
and II) in the gene. Splice I inserts or omits exon 5 (17 amino
acids) and splice II occurs within the zinc ¢nger domain, in-
serting or omitting three amino acids (lysine, threonine and
serine, KTS) between zinc ¢ngers 3 and 4 [10]. We refer to the
di¡erent isoforms according to insertion [+] or omission [3] at
splice sites I and II, respectively, so that, for example, isoform
[+/3] has an insertion at splice site I, but not at splice site II.
The relative abundance of each isoform appears to be ¢xed
both during human kidney development and in Wilms’ tu-
mours in a ratio of 8.3 [+/+]:3.8 [3/+] :2.5 [+/3] :1.0 [3/3]
[10]. The [3KTS] and [+KTS] WT1 isoforms have di¡erent
but overlapping DNA binding speci¢cities. WT1[3KTS] has a
zinc ¢nger domain more closely resembling that of EGR-1
and, accordingly, interacts with the EGR-1 consensus se-
quence (CGCCCCCGC) [11], whereas WT1[+KTS] does
not. The latter zinc ¢nger domain can, however, bind a broad-
er range of (G+C)-rich DNA elements for which a consensus
has not emerged (reviewed in [12]). In addition to these
(G+C)-type WT1 binding sites, a (TCC)-repeat motif which
is bound by both [+KTS] and [3KTS] isoforms of WT1 has
been identi¢ed [13]. Both of these isoforms can also bind
RNA [14]. Alternative WT1 proteins are also generated by
RNA editing [15] and alternative translational initiation [16],
giving a total of 16 possible isoforms. The functional distinc-
tion between all the WT1 isoforms, however, remains elemen-
tary, with [3KTS] isoforms generally considered as transcrip-
tional regulators and [+KTS] isoforms regarded as RNA
metabolism co-factors.
Many other genes have been proposed as potential targets
for repression by WT1, by virtue of (G+C)-rich WT1 consen-
sus binding sites in their promoters. Some of these genes en-
code potent mitogens that could contribute to tumourigenesis
when derepressed. In transient co-transfection assays, WT1
represses transcription from numerous such promoters, for
example EGR-1, IGF-2, IGF-1-R, C-MYC and C-MYB
[11,17^20]. The expression pattern of WT1 may also be modu-
lated by negative autoregulation via interaction of WT1 pro-
tein with the WT1 5P promoter [21,22].
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Our previous work identi¢ed an antisense WT1 promoter
located in the ¢rst intron of the WT1 gene that was trans-
activated rather than repressed by WT1 [23]. This led us to
hypothesise that activation of the antisense promoter might
represent a further feedback loop regulating WT1 expression.
Antisense RNAs encompassing WT1 exon 1 and the WIT-1
gene [24] occur in foetal kidney and Wilms’ tumours [25,26]
and are expressed in parallel with sense WT1 mRNA [27]. The
apparent lack of coding capacity and expression pattern
strongly suggest that the antisense transcript may be a regu-
latory RNA which contributes to the overall control of WT1
protein levels. Indeed, we have recently shown that expression
of antisense WT1 exon 1 RNA in 293 cells stably expressing
exogenous WT1 upregulates WT1 protein levels [27]. A num-
ber of vertebrate genes, including human N-MYC [28],
C-MYC [29], chick type I collagen K1 chain [30] and chick
fgf-2 [31] have cognate endogenous antisense RNAs with po-
tential regulatory roles.
Unlike the numerous in vitro co-transfection studies report-
ing WT1-mediated promoter repression, our results exhibited
WT1-mediated activation of a full-length, natural promoter.
The promoters for EGR-1 [32] and IGF-2 [33] have been
shown to be activated by WT1 in cell-lines lacking wild-type
p53, with the transcriptional e¡ect of WT1 reverting to repres-
sion in the presence of wild-type p53. However, our previous
studies have shown that the WT1 sense (repressed) and anti-
sense promoters (activated) are reciprocally regulated in the
same cells [21,23], suggesting to us that there are other im-
portant di¡erences between the mechanisms of WT1-mediated
transcriptional activation and repression.
Quantitative perturbations of WT1 expression have been
implicated in the pathogenesis of DDS [34], Frasier syndrome
[35] and breast cancer [6], the former on the basis of gene
dosage and the latter two by altered levels of WT1 isoforms.
It therefore remains imperative to categorise factors in£uenc-
ing WT1 gene expression and also the individual roles of the
various WT1 isoforms. In this study, we address both ques-
tions by investigating the interaction of isoforms with a WT1
regulatory element, namely the antisense promoter. Although
previous reports of promoter regulation by WT1 show that
activity is independent of alternative splice I (reviewed in [12]),
we demonstrate that transactivation of the antisense promoter
is unique to the WT1[+/3] isoform and that WT1 binding to
(G+C)-rich consensus sites within the antisense promoter
alone does not account for activity. The data presented high-
light a potential speci¢c role for the WT1[+/3] isoform and a
complex control point in normal WT1 gene expression which
may be disrupted in disease.
2. Materials and methods
2.1. Promoter-reporter construction and nucleic acids
Plasmid pEWTY contains a 734 bp DNA fragment spanning posi-
tions 3647^+87 of the human WT1 antisense promoter [23]. This was
produced by polymerase chain reaction (PCR) with primers TM-2 and
TM-4 (see Fig. 1A) and cloned into the luciferase reporter plasmid
pGL2E (Promega), using standard sub-cloning techniques [36]. The
WT1 consensus site mutants pE-180m and pE-544m were ampli¢ed
with their respective mutated primers (see Table 1), followed by over-
lapping PCR with TM-2 and TM-4. Lastly, the double mutant pE-dm
was cloned by combining mutated components from pE-180m and
pE-544m. Vectors expressing murine WT1 cDNAs encoding each of
the four WT1 isoforms [+/+, þ , 3/+, 3/3] from a CMV promoter
were kindly supplied by N. Hastie.
293 cells were maintained as previously described [21]. Transient
transfections were performed as previously described [23] except
that no internal control plasmid was used. Each experiment was re-
peated in triplicate at least three times. Extracts were prepared and
assayed for luciferase activity according to the manufacturer’s proto-
cols (Promega).
2.2. Western analysis
Total cellular protein was isolated from transfected 293 cells and
analysed by Western blotting as described previously [21].
2.3. Preparation of recombinant WT1 fusion protein and nuclear
extracts
WT1 zinc ¢nger-GST fusion protein expression vectors pGEXREV,
pGEX-KTS (kind gifts of A. Ward) and pGEXS+KTS (kind gift of
M. Little) each contain a 460 bp BamHI fragment encoding residues
313^449 of human WT1 cDNA. pGEXREV contains the cDNA in
reverse orientation. Each was used to transform Escherichia coli
HB101 from which clonal cultures were grown and then induced
with 1 mM IPTG for 4 h. Cells were harvested, washed and protein
was isolated using glutathione agarose beads (Sigma) according to the
manufacturer’s protocol. Nuclear extracts were prepared from con£u-
ent monolayers of 293 cells as described by Dent and Latchman [37].
2.4. Electromobility shift assay (EMSA)
Oligonucleotides were annealed in 1 mM Tris-HCl, pH 8.0, 1 mM
MgCl2, by heating to 80‡C and then cooling slowly. 1.75 pmol double
strand oligonucleotide was end-labelled using 0.37 MBq [Q-32P]ATP
(3000 Ci/mmol, NEN 32P) and T4 polynucleotide kinase (Immunogen
International) after which the probe was diluted to 0.175 pmol/Wl with
TE and then stored at 320‡C. Fusion protein quanti¢ed by a Bio-Rad
protein assay was mixed with 1Wg poly-dI/poly-dC in 20 Wl total
volume of bu¡er P (1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT,
50 mM NaCl, 10 mM Tris, pH 7.5, 4% glycerol) and pre-incubated on
ice for 15 min. After addition of 1 Wl diluted probe, incubation con-
tinued for 20^30 min. Reactions were loaded onto a 5% non-denatur-
ing polyacrylamide gel (80:1 acrylamide:bis-acrylamide, 0.5UTBE)
and run at 100 V for 2 h. Gels were dried and autoradiographed
with Hyper¢lm MP (Amersham International).
3. Results
3.1. Transactivation of the antisense promoter is speci¢c for the
WT1[+/3] isoform
Our previous studies demonstrating WT1-mediated trans-
activation of the antisense promoter utilised a 293 cell-line
derivative stably transfected with a human WT1[+/3] express-
ing construct [23]. In this study, we assessed the e⁄cacy of
transactivation by other WT1 isoforms by co-transfection of
the antisense promoter with mouse WT1 isoforms constitu-
tively expressed by a CMV promoter. The native promoter
plasmid employed, pEWTY, is depicted in Fig. 1A and in-
cluded 87 bp downstream of the previously determined tran-
scriptional start site to ensure that transactivation was not a
consequence of deleting cryptic binding sites 3P of the tran-
scriptional start site.
In marked contrast to the WT1 sense promoter which is
auto-repressed by all WT1 isoforms [22], transient co-trans-
fection assays in 293 cells revealed that the [+/3] isoform
transactivated the antisense promoter to a level of approxi-
mately 3.5-fold over controls. At similar levels of expression
(shown in Fig. 1C), three of the four WT1 isoforms, [3/3],
[3/+] and [+/+], had no signi¢cant e¡ect on the antisense
promoter above control levels found in the absence of WT1
(Fig. 1B). The level of transactivation of the antisense pro-
moter is quantitatively similar to that previously demon-
strated for 293 derivatives stably expressing exogenous human
WT1[+/3] [23], indicating that the speci¢city of transactiva-
tion is not a consequence of species variation or choice of
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Fig. 1. Activation of the WT1 antisense promoter by WT1 isoforms. (A) Schematic representation of the WT1 antisense promoter in pEWTY.
Putative binding sites for WT1 (closed box), Sp1 (open box), Ap1 (hatched box), Ap2 (cross-hatched box) and Pax-2 (stippled box) are shown.
Restriction sites, the transcription start site (TSS) and primers TM-4 and TM-2, used for amplifying the fragment, are indicated. Numbers are
relative to the TSS (+1). (B) Luciferase activities of antisense promoter/luciferase reporter plasmids co-transfected with each WT1 isoform.
293 cells were co-transfected with pEWTY and the expression vectors: WT1[+/+], WT1[+/3], WT1[3/+], WT1[3/3] or an empty RcCMV cas-
sette as control (C). The luciferase values obtained are expressed as a proportion of the activity found using RcCMV. Results are mean þ
S.E.M. of at least three experiments performed in triplicate. (C) Western analysis of WT1 isoforms proteins from 293 cells transfected with
each WT1 expression vector ( þ , +/+, 3/+ and 3/3) or empty cassette as control (C) were analysed by Western blotting, probed with anti-
WT1 (C-19) antibody. Untransfected cells (U) and T5A1 cells constitutively expressing WT1[+/3] from an uninduced metallothionein promoter
(T) are shown as negative and positive controls, respectively. (D) Luciferase activities of mutated antisense promoter/luciferase reporter plas-
mids co-transfected with WT1[+/3]. Mutated derivatives of pEWTY, pE-180m, pE-544m and pE-dm were constructed as described in Section
2. The scheme indicates whether the consensus sites at 3544 and 3180 are wild-type (closed box) or mutant (open box) in each plasmid. Luci-
ferase activities are shown for each plasmid co-transfected into 293 cells with WT1 isoform expression plasmid WT1[+/3] (hatched bars) or
empty cassette as control, RcCMV (stippled bars). Luciferase values obtained were expressed as a proportion of the activity found using
pEWTY and RcCMV. Results are mean þ S.E.M. of at least three experiments performed in triplicate.
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expression vector. Amongst the plethora of transfection stud-
ies of transcriptional regulation by WT1, this is the ¢rst report
of regulation by a single speci¢c isoform. The necessity for
WT1[3KTS] suggested that binding to classical EGR-type
consensus sequences was, as expected, a key determinant for
transactivation. More surprisingly, however, alternatively
spliced exon 5, previously shown to be essential for repression
of the PDGF-A promoter [38], is obligatory for transactiva-
tion of the antisense promoter.
3.2. DNA binding requirements for transactivation
Our transfection studies show a precise requirement for
splice I inclusion and splice II exclusion for WT1 antisense
promoter transactivation. Splice II is located in the DNA
binding zinc ¢nger domain of WT1, so we therefore assessed
the e¡ect of mutating two WT1 consensus binding sites within
the promoter [23] and the binding of WT1 zinc ¢nger fusion
proteins to these sites.
Derivatives of the full-length antisense promoter-reporter
plasmid pEWTY were constructed by PCR-based mutagene-
sis. Mutations were generated in either one or both of the
WT1 sites while retaining putative Sp1 core binding sites
(GGGCGG at 3180 and GGGCCG at 3544). Sequences of
each WT1 site and its mutated derivatives were con¢rmed by
DNA sequencing and are displayed in Table 1. We co-trans-
fected 293 cells with pCMV-WT1[+/3] or RcCMV control
plasmid and antisense reporter constructs carrying either
wild-type (pEWTY) or mutated WT1 sites (pE-180m, pE-
544m and pE-dm, representing mutations at sites 3180,
3544 and both sites, respectively).
As shown in Fig. 1D, pEWTY was activated approximately
3.5-fold by WT1 co-transfection. Antisense promoter con-
structs with mutations in one or both WT1 consensus sites
were activated to a similar degree as pEWTY by WT1 (be-
tween 3- and 3.7-fold), demonstrating that the WT1 consensus
sites at 3180 and 3544 are not required for transcriptional
activation of the antisense promoter. We also performed EM-
SAs using oligonucleotide probes representing each WT1 con-
sensus and found that neither WT1[3KTS] nor WT1[+KTS]
fusion proteins bound the site at 3180 (Fig. 2B), con¢rming
Table 1
Sequences of wild-type and mutated WT1 sites in the antisense pro-
moter
Location Allele Sequence
3544 wt 5P-GCTTCGCGGGGGCCGGGTGCTC
3544 m 5P-GCTTCAAAAGGGCCGCATGCTC
3180 wt 5P-AAGAGAGGTGGGCGGGCATCGG
3180 m 5P-AAGAGAAAAGGGCGGCAAT
Nucleotide sequences are given showing potential WT1 binding sites
(underlined) and Sp1 boxes (bold) in the antisense promoter. Oligo-
nucleotides corresponding to the mutated alleles (m) were used to
create reporter plasmids carrying mutations at one or both WT1
sites as described in Section 2. Complementary oligonucleotides
were annealed to oligonucleotides of the above sequences to provide
wild-type (wt) and mutated (m) probes as described in Section 2.
Fig. 2. EMSA of antisense promoter sites 3544 and 3180 and WT1 zinc ¢nger-GST fusion proteins. (A) Both WTZF[3KTS] and [+KTS]
form a complex with site 3544. Oligonucleotide probe 3544 was labelled with 32P and incubated (as described in Section 2) with
WTZF[3KTS] (3), lanes 2^4; WTZF[+KTS] (+), lanes 5^7; no protein (0), lane 1; or reverse expression product (R), lane 8. The triangle rep-
resents decreasing concentrations of protein. Lanes 2 and 5, 0.2 Wg; lanes 3 and 6, 0.1 Wg; lanes 4 and 7, 0.05 Wg. F, free probe; C, complex.
(B) WTZF does not form a complex with consensus site 3180 or a mutated version of site 3544. Oligonucleotide probes corresponding to
antisense promoter positions 3544, 3180 and a mutated version of site 3544 (sequences shown in Table 1) were used in EMSA. Probes were
as follows: lanes 1 and 2, probe 3544 (3544); lanes 3^7, probe 3180 (3180); lanes 8^10, mutated probe 3544 (3544M). Proteins were as fol-
lows: lanes 3 and 8, no protein; lanes 2, 7 and 10, 0.7 Wg reverse expression product (R); lanes 1 (0.3 Wg), 4^6 and 9 (0.7 Wg), WTZF[3KTS]
(WT1). The triangle represents decreasing protein titres. Lane 4, 0.7 Wg; lane 5, 0.5 Wg; lane 6, 0.3 Wg. F, free probe; C, complex. (C) Antibody
to WT1 super-shifts WTZF site 3544. EMSA was performed as in A but with a constant amount of WTZF (WT1) (0.3 Wg WTZF[3KTS]),
lanes 2^5. Lane 1, no protein (0). Increasing titres of antibody are represented by the triangle: lane 3, 0.1 Wg; lane 4, 0.5 Wg; lane 5, 1.0 Wg. F,
free probe; C, complex, S, super-shift.
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that this is not a target for WT1. Interestingly, site 3544 is
bound by both fusion proteins in EMSA (Figs. 2A and B) and
the mutated site 3544 is not (Fig. 2B), even though the cor-
responding transfection construct, pE-544m, remains transac-
tivatable by WT1[+/3]. This may re£ect an uncharacterised
context dependency for binding and transactivation.
The reduced mobility band formed in the presence of
WTZF-GST is super-shifted when anti-WT1 antibody is in-
cluded (Fig. 2C), con¢rming that the reduced mobility of the
probe is due to WT1 binding. Although we cannot exclude
WT1 binding to as yet uncharacterised sites, our results in-
dicate that the DNA binding capability is clearly not su⁄cient
for transactivation of the antisense promoter. Furthermore,
the speci¢c transactivation by WT1[+/3] cannot be attributed
solely to di¡erential DNA binding arising from inclusion or
omission of splice II, again emphasising the importance of
splice I in transactivation of this promoter.
We note that the mutated promoter constructs showed
slightly lower basal transcription levels (with RcCMV control
plasmid) than pEWTY, but this was not statistically signi¢-
cant (Ps 0.05, Dunnett’s t-test). The ratio of expression levels
in the presence and absence of WT1 for all four plasmids is,
however, similar (between 3.0 and 3.7), showing that the mu-
tated promoter sequences are activated by WT1 to a similar
extent as the wild-type promoter.
4. Discussion
The regulation of WT1 protein levels depends upon an in-
creasingly complex series of interactions between a variety of
proteins and DNA elements. These include increased expres-
sion via a haematopoeitic cell-speci¢c enhancer located 3P of
the gene [39], induction by pax-2 and pax-8 in the developing
kidney and urogenital system [40,41] and negative feedback of
WT1 transcription via (G+C)-rich sites in its own promoter
[21,22]. These control mechanisms may be further augmented
by cellular WT1 antisense RNAs [24^26] for which we have
previously identi¢ed a promoter [23] and shown a positive
correlation between levels of antisense RNA and WT1 protein
expression [27]. Interestingly, although WT1 functions widely
as a transcriptional repressor, we found it to activate antisense
transcription, indicating that transcriptional regulation by
WT1 may be promoter-speci¢c and exerted by more than a
single mechanism.
There are few previous reports of a transactivation function
for WT1 on natural promoters. Recently, the SRY promoter
has been shown to be transactivated by WT1[3KTS] with an
isoform-speci¢city attributable to di¡erential DNA binding by
[3KTS] and [+KTS] variants to WT1 consensus sites [42]. In
contrast to the transactivation of the antisense promoter, the
presence or absence of exon 5 at splice I had no e¡ect on
transactivation. Similarly, transactivation of the Syndecan-1
promoter is also indiscriminate for WT1 isoforms [43] as are
other promoters repressed in trans by WT1 (reviewed in [12]).
Two further examples of transactivation have been in a cel-
lular background de¢cient in wild-type p53. In cell-lines lack-
ing wild-type p53, WT1 has been found to activate transcrip-
tion from promoters with EGR-1 consensus sites and
reconstitution of wild-type p53 reduced the level of activation
or resulted in repression [32]. Also, the expression of endog-
enous IGF-2 in the RM1 Wilms’ tumour cell-line, which ex-
presses a mutated p53 gene, is induced by transfected WT1
[33]. Although we have not investigated the p53 status of 293
cells used in our study, we have previously shown that WT1
represses its own (G+C)-rich promoter in the same cells [21].
This reciprocal regulation of sense and antisense promoters
indicates that the di¡erences in their activities cannot be ac-
counted for simply by tissue-speci¢c trans-acting factors such
as p53, but may also involve the speci¢c cis-sequence contexts
of the promoters and the assembly of promoter-speci¢c tran-
scriptional complexes.
Previous reports of both promoter repression and activa-
tion show a dependence upon binding of WT1 protein to
DNA, usually at (G+C)-rich sites. We have found that trans-
activation of the antisense promoter is independent of two
putative binding sites upstream of the transcription start
site. The isoform-speci¢city of antisense promoter transactiva-
tion may be attained by interaction of WT1[+/3] with an
accessory factor. The N-terminus of WT1 contains poly-pro-
line and glutamine-rich tracts which Madden et al. have dem-
onstrated to repress transcription when fused to a heterolo-
gous DNA binding domain [44]. This e¡ect was reported as
being much more pronounced in NIH3T3 than 293 cells, im-
plicating interaction of WT1 with other cell-speci¢c factors.
Similarly, repression of the PDGF-A promoter was released
by competition of a DNA binding domain-deleted WT1 pro-
tein with the wild-type protein [45], indicating protein-protein
interaction. More recently, several WT1 interacting proteins,
hubc-9, par-4, ciao-1 and hsp70 [46^49], have been isolated
using the yeast two-hybrid system and shown to modulate the
transcriptional regulatory abilities of WT1. Although interest-
ingly, some of these bind to the C-terminal zinc ¢nger domain
of WT1. These examples add to the abundant evidence to
suggest that functions of WT1 can be modulated by interac-
tion with accessory factors. Our results indicate that trans-
activation of the WT1 antisense promoter is speci¢cally de-
pendent upon the insertion of these 17 amino acids at splice I
and we postulate that their function is to allow interaction
with other nuclear factors. This would provide a mechanism
for cell-speci¢c factors to feed into the complex pathways
regulating WT1 levels.
The discovery of isoform-speci¢c functions for WT1, such
as we report, is especially pertinent as there is increasing evi-
dence of WT1 isoform imbalance being associated with dis-
ease. Aberrant splicing of KTS variants has been reported in
Frasier syndrome [35] and WT1 splice variants lacking splice I
and/or splice II are increased in breast tumours relative to
normal tissue [6]. More recently, a sporadic WT was shown
to have a mutation within exon 5, resulting in the production
of a tumour-speci¢c WT1 protein with decreased activity rel-
ative to the wild-type protein in assays of transcriptional re-
pression and growth inhibition [50]. Further sporadic WTs
have also been shown to have altered levels of exon 5 splice
forms [51]. Such variations may result in altered expression of
downstream WT1 target genes, with pleiotropic consequences
for cell growth. Our results further suggest the possibility of a
cascade of deregulation arising from inappropriate isoform
expression and interaction with WT1 regulatory elements.
Clearly, the complete elucidation of WT1 isoform functions
will greatly expand our understanding of the developmental
processes and diseases in which WT1 may be involved.
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